The Aug. 15 post was in reference to Mark Cuban’s comments about shaking up the industry. Mark Cuban Cost Plus Drugs Co. will publish its contracts, the entrepreneur said on “The Daily Show” on Aug. 12.
Mr. Wexler, who currently is COO of the Renton, Wash.-based system, said Mr. Cuban’s drug pricing critique is understandable. Mr. Wexler added that disruption is often misunderstood, saying that it should be done “in alignment with patients, providers and payers.”
Implementing programs that address health inequity is one way Providence has welcomed thoughtful disruption, he said.
“When it comes to disruption, we must ask whether it will improve healthcare outcomes and access for everyone, or if it only benefits special interests that conflict with doing the best for those who need care,” Mr. Wexler wrote.
At Becker's 4th Annual CEO + CFO Roundtable, taking place November 2–5 in Chicago, more than 1,500 hospital and health system executives tackle decisions that determine whether organizations thrive or merely survive: protecting margins under cost pressure, choosing where to grow, renegotiating payer relationships, stabilizing the workforce and proving real ROI on technology. This is where leaders work through them together, face-to-face. Apply for complimentary registration now.
